BioCentury
ARTICLE | Regulation

Serving nerves

How patient and industry priorities match up in HD, PD

September 28, 2015 7:00 AM UTC

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression and improve psychiatric and cognitive symptoms, although it will be difficult to demonstrate those effects in the clinic.

In Parkinson's disease, there appears to be a clearer route to meeting patient needs with clinical programs focused on solving PK problems with existing drugs to enable better motor control...